Skip to content
10-Q

Quarterly Report

Alto Neuroscience, Inc. ANRO

0001999480-25-000037

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 27.07M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $19.94M
Long Term Debt Q1 2025 · Dec 31, 2024 $10.25M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $160.75M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $168.23M
Current Liabilities Q1 2025 · Mar 31, 2025 $7.26M
Current Liabilities Q1 2025 · Dec 31, 2024 $10.01M
Total Liabilities Q1 2025 · Mar 31, 2025 $32.82M
Total Liabilities Q1 2025 · Dec 31, 2024 $26.08M
Current Assets Q1 2025 · Mar 31, 2025 $163.52M
Current Assets Q1 2025 · Dec 31, 2024 $169.34M
Total Assets Q1 2025 · Mar 31, 2025 $171.92M
Total Assets Q1 2025 · Dec 31, 2024 $177.54M
Shares Diluted Q1 2025 · Mar 31, 2024 17.6M sh
Capex Q1 2025 · Mar 31, 2024 $224K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$10.98M
Stockholders Equity Q1 2025 · Mar 31, 2024 $193.1M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$71.67M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.76
Eps Basic Q1 2025 · Mar 31, 2024 −$0.76
Sga Expense Q1 2025 · Mar 31, 2024 $4.43M
Rd Expense Q1 2025 · Mar 31, 2024 $9.95M
Net Income Q1 2025 · Mar 31, 2024 −$13.42M
Operating Income Q1 2025 · Mar 31, 2024 −$14.39M